2024-06-25
Target
Deal Size
Buyer
This week’s hot transaction we have selected is the collaboration between Roche and Ascidian based on RNA exon editing technology signed on June 18th. Roche will pay Ascidian an upfront and milestone payment of up to $1,842 million to obtain the global exclusive license for Ascidian technology platform, EXTEND™ RNA exon editing technology, applied in the field of central nervous system (CNS) diseases. The two parties will jointly develop drugs based on the technology for the treatment of neurological diseases such as Parkinson’s disease and Alzheimer’s disease.
RNA exon editing is an emerging gene editing technology that can precisely regulate gene expression by changing the splicing process of RNA, and it is expected to be used to treat a variety of diseases. Compared with traditional gene editing technologies such as CRISPR, RNA exon editing can achieve higher precision and safety by optimizing gRNA design and the combination of various editing enzymes, and it does not make permanent modifications to DNA.
Through the cooperation with Roche, Ascidian can continuously evaluate and optimize the risks and efficiency of its large fragment editing technology through multi-omics, and at the same time, it is expected to explore more applications in other diseases based on the maturity of Roche’s delivery technology platform in the future.
Peter Zhang
Partner, YAFO Capital
Target
Deal Size
Buyer
本周热点交易我们选择了Roche与Ascidian于6月18日达成的基于RNA外显子编辑技术的合作。Roche将支付Ascidian最高18.42亿美元的首付款和里程碑付款，以获得Ascidian开发的技术平台EXTEND™RNA外显子编辑技术在中枢神经系统（CNS）疾病领域的全球独家许可权。双方将共同开发基于该技术的药物，用于治疗帕金森病、阿尔茨海默病等神经系统疾病。
RNA外显子编辑是一种新兴的基因编辑技术，通过改变RNA的剪接过程，可以精确地调控基因表达，有望用于治疗多种疾病。与传统的基因编辑技术如CRISPR相比，RNA外显子编辑可以通过优化gRNA设计，多种编辑酶的组合获得更高的精确性和安全性，而且不会对DNA进行永久性修改。
通过与罗氏的合作，Ascidian可以通过多组学持续评估及优化其大片段剪辑技术的风险和效率，同时未来有望根据罗氏的递送技术平台的成熟在其他疾病领域发掘更多的应用。
Peter Zhang
Partner, YAFO Capital
1. Summary of the week
From June 15 to 21, a total of eight licensing and cooperation deals were signed globally. In the China Biotech Industry, there was one out-licensing deal between MabCare Therapeutics and Day One Biopharma for a pre-clinical stage asset, totaling $1.207 billion with an upfront payment of $55 million.
Globally, seven licensing and cooperation deals were sealed. The standout deal of the week was between Ascidian Therapeutics and Roche for RNA exon editing technology, amounting to a total of $1.842 billion with an upfront payment of $42 million.
6月15日-21日，全球共达成8项资产授权与合作交易。中国医药市场仅有1项出海交易。Day One Biopharma和麦科思生物就后者一临床前资产PTK7 ADC达成授权交易，首付款5500万美元，总金额12.07亿美元。
国际市场上，共签署了7项资产授权与合作交易。其中最值得关注的交易是Roche与Ascidian之间签署的基于RNA外显子编辑技术的合作，首付款4200万美元，总金额18.42亿美元。
2. Licensing Deals
2a. China section
2b. Global section
3. Top Deals of the year 2024
4. 2019-2023 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions in the past three years. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
ACCESS CHINA
Event Name: ACCESS CHINA Networking & Gathering @BIO
Date & Time: June 2-6, 2024
Venue: San Diego
Content: Reception, 1X1 meetings
Participants: Pharma/Biotech senior management and BDs.
Registration Link: https://jinshuju.net/f/AqkB9m?x_field_1=BIO
BioToChina.org 